MacroGenics Inc (MGNX) Stock Analysis

MacroGenics Inc (MGNX) is a publicly traded company in the HEALTHCARE sector. It trades at $4.05, carries a market capitalization of $263.15M. This page summarizes the public market data, fundamentals, and frequently asked questions for MGNX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $4.05
• Market Cap: $263.15M
• EPS: $-1.11
• 52-Week High: $4.64
• 52-Week Low: $1.19

Market Sentiment

MacroGenics Inc currently has a Neutral sentiment score of 0.14.

About MacroGenics Inc

MacroGenics, Inc. is a clinical-stage biopharmaceutical company based in Rockville, Maryland, focused on developing cutting-edge antibody-based therapies for cancer treatment. Utilizing proprietary technology platforms, MacroGenics seeks to address critical unmet medical needs in oncology through a robust pipeline of differentiated drug candidates. By establishing strategic partnerships and advancing its clinical programs, the company is poised to enhance treatment options and patient outcome...

GNG Research Analysis

GNG Research scores MacroGenics Inc (MGNX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for MGNX.

Frequently Asked Questions

Does MGNX pay dividends?

MacroGenics Inc (MGNX) does not currently pay a regular dividend.

What is MGNX's market cap?

MacroGenics Inc (MGNX) has a market capitalization of $263.15M with a current stock price of $4.05.